Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes - Top-Institutions - MDSpire

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

  • By

  • Wei Zhao

  • Lingli Zhou

  • Ying Gao

  • Xianghai Zhou

  • Xueyao Han

  • Xiuying Zhang

  • Linong Ji

  • July 15, 2026

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Peking University People’s Hospital
    Peking University People’s Hospital

    Beijing, Beijing

    Key Differentiators

    • Endocrinology

Original Source(s)

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

  • by Wei Zhao, Lingli Zhou, Ying Gao, Xianghai Zhou, Xueyao Han, Xiuying Zhang, Linong Ji

  • July 15, 2026

Related Content

Steroid Strategies in Diabetic Macular Edema

AI Screening for Diabetic Retinopathy

Diabetes Mellitus Coding in Retina

Age-related macular degeneration (AMD) is among the most common retinal diagnoses. Although the clinical features of the disease are well known, ICD-10 coding can be confusing if details such as stage, activity, and laterality are not clearly documented. Incomplete documentation may prompt questions about the medical necessity of diagnostic tests or intravitreal injections. This Q&A addresses common sources of confusion and offers practical guidance to support clear, accurate documentation.